![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 305, Issue 1, 159-166, April 2003
The Department of Pharmaceutical and Biomedical Sciences, The Raabe College of Pharmacy, Ohio Northern University, Ada, Ohio (J.E.S., M.L.B., V.J.C.); and National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland (E.M.M.)
| |
Abstract |
|---|
|
|
|---|
An acute and potentially life-threatening complication associated with
the recreational use of the 3,4-methylenedioxymethamphetamine (MDMA,
Ecstasy) is hyperthermia. In the present study, Sprague-Dawley rats
treated with MDMA (40 mg/kg s.c.) responded with a significant increase
(maximal at 1 h) in rectal and skeletal muscle temperatures that
lasted for at least 3 h post-treatment. Hypophysectomized (HYPO)
and thyroparathyroidectomized (TX) animals treated with MDMA (40 mg/kg
s.c.) did not become hyperthermic and in fact displayed a significant
hypothermia. The HYPO and TX animals were also resistant to the
serotonergic neurotoxic effects of MDMA assessed by serotonin measurements 4 to 7 days later in the striatum and hippocampus. MDMA
(40 mg/kg s.c.) induced a significant increase in thyroxine levels
1 h post-treatment. Thyroid hormone replacement in TX animals returned the hyperthermic response seen after MDMA. Prazosin, an
1-antagonist (0.2 mg/kg i.p.), administered 30 min
before MDMA significantly attenuated the MDMA-induced increase in
rectal temperature, but had no effect on skeletal muscle temperature. Cyanopindolol, a
3-antagonist (4 mg/kg s.c.),
administered 30 min before MDMA (40 mg/kg s.c.) significantly
attenuated the increase in skeletal muscle temperature, but had no
effect on the rise in rectal temperature. The combination of prazosin
and cyanopindolol resulted in an abolishment of MDMA-induced
hyperthermia. The mechanisms of thermogenesis induced by MDMA seem to
result from an interaction between the hypothalamic-pituitary-thyroid
axis and the sympathetic nervous system, wherein mechanisms leading to
core and skeletal muscle hyperthermia after MDMA exposure seem to be
differentially regulated by
1- and
3-adrenergic receptors.
| |
Introduction |
|---|
|
|
|---|
The
substituted amphetamine 3,4-methylenedioxymethamphetamine (MDMA,
ecstasy) is commonly associated with an increase in body temperature in
both humans (Dar and McBrien, 1996
; Mallick and Bodenham, 1997
) and
rodents (Gordon et al., 1991
). Because of its association with weekends
and rave parties, emergency room personnel often refer to severe forms
of this hyperthermia as "Saturday Night Fever" (Williams et al.,
1998
), which can be associated with rhabdomyolysis, multiorgan failure,
and death (Walubo and Seger, 1999
). Although deaths from overdose
remain rare, the prevalence and especially hospitalizations resulting
from MDMA exposure have dramatically increased from 250 hospitalizations in 1994 to over 2850 in 1999 (Drug Abuse Warning
Network, 2000
). Much evidence from rodent and nonhuman primate studies
suggests that MDMA also induces long-term serotonergic neurotoxicity
that seems to be ostensibly linked to hyperthermia (Broening et al.,
1995
; Farfel and Seiden, 1995
; Malberg et al., 1996
). Although the
importance of their elucidation cannot be overstated, the fundamental
biological mechanisms involved in heat production and progression to
hyperthermia after MDMA exposure are unknown. Furthermore, we do not
understand clearly the associations between hyperthermia and many of
the pathological changes induced by MDMA.
Gordon et al. (1991)
proposed that MDMA induces a dysfunction in
central nervous system thermoregulatory mechanisms that are influenced by ambient temperature. Several laboratories have shown that
when MDMA is given to rats in a 24°C or greater environment, hyperthermia results (Schmidt et al., 1990
; Gordon et al., 1991
). If
the ambient temperature is lowered to 10°C, however, a hypothermic response occurs (Gordon et al., 1991
). The set point for either a
hyperthermic or hypothermic response seems to be above or below 20-22°C (Gordon et al., 1991
; Malberg and Seiden, 1998
) with most neurotoxicity studies being conducted at 23-24°C.
In addition to evidence suggesting that MDMA acutely disturbs central
nervous system thermoregulatory functions, MDMA-induced activation of
the sympathetic nervous system (SNS) and subsequent alterations in
vascular hemodynamics may also play an important role in heat
production and redistribution. Peripheral heat production in organs
such as brown and white fat and skeletal muscle is regulated in part by
norepinephrine (Bianco et al., 1988
; Rubio et al., 1995a
,b
). Recently,
Pedersen and Blessing (2001)
showed that MDMA induces cutaneous
vasoconstriction and that this cutaneous restriction in blood flow
contributes to the increase in core body temperature seen after
treatment with MDMA. These authors also showed that sympathectomy only
partially attenuated the hyperthermic response seen after MDMA.
Recently, Fernandez et al. (2002)
showed that ganglionic blockade only
partially attenuated the hyperthermic effect induced by MDMA. Taken
together, these studies suggest that the hyperthermic response to MDMA
involves more than merely the activation of the SNS and changes in
regional blood flow.
Thyroid hormone is the primary endocrine regulator of metabolism and
thermogenesis. Surprisingly, there seem to be no studies that have
directly examined the role of thyroid hormone in the hyperthermic
response to MDMA. Three lines of evidence suggest that thyroid hormone
may be linked to the hyperthermic response to MDMA. 1) Fekete et al.
(2000)
observed that amphetamines induce the cocaine- and
amphetamine-regulated transcript in the hypothalamic paraventricular
nucleus, resulting in an increased biosynthesis of
thyrotropin-releasing hormone. This study predicts that MDMA may also
increase thyroid hormone levels. 2) At the cellular level, thyroid
hormone seems to play both a permissive and synergistic role in
norepinephrine- or SNS-mediated thermogenesis (Bianco et al., 1988
;
Rubio et al., 1995a
,b
). According to recent evidence, these effects may
be mediated by a family of mitochondrial uncoupling proteins (UCP),
members of which mediate nonshivering thermogenesis (Argyropoulos and
Harper, 2002
). 3) The synergism between thyroid hormone and
norepinephrine-dependent mechanisms of thermogenesis, including the
activation and transcriptional regulation of UCP (Gong et al., 1997
),
seems to be mediated specifically by the thyroid hormone receptor and
1- and
3-adrenergic
receptors (Silva, 1995
).
Because the role, if any, that thyroid hormone plays in MDMA-induced hyperthermia is not known, we examined the role of and the interactions between the SNS and the hypothalamic-pituitary-thyroid (HPT) axis in the development of the hyperthermia induced by MDMA. We hypothesized that MDMA administration would induce an increase in thyroid hormone levels, ultimately facilitating norepinephrine-mediated thermogenesis. Furthermore, we predicted, as evidence would suggest, that acute hyperthermia plays a prominent role in MDMA-induced chronic neurotoxicity.
| |
Materials and Methods |
|---|
|
|
|---|
The present study was carried out in accordance with protocols approved by the Ohio Northern University Animal Care and Use Committee.
Animals. Sham, hypophysectomized (HYPO), and thyroparathyroidectomized (TX) adult male Sprague-Dawley rats (weighing 175-200 g) were obtained from Harlan (Indianapolis, IN). All animals were housed in groups of three and given ad libitum access to food and drinking water. Housing conditions were maintained at a constant temperature of 23°C and a 12:12-h light/dark cycle. For hypophysectomy, anesthetized animals were placed in a ventral recumbency in a Hoffman-Reiter hypophysectomy instrument. A 19-gauge needle was inserted through the hollow right ear bar. The needle was pushed through the bone with the bevel side down until the needle stopper made contact with the ear bar. The needle was rotated in a semicircle two or three times. The needle was then rotated so the bevel pointed downward and the pituitary was slowly aspirated into the water-filled syringe. The pituitary was then examined to ensure complete removal. Once confirmed, HYPO animals were given 5% sucrose solution as a drinking source for 5 days postsurgery. For thyroparathyroidectomy, anesthetized animals had the ventral cervical area shaved and swabbed with surgical scrub. A 1- to 1.5-cm midventral incision was made from just caudal to the pharynx to the cranial edge of the pectoral muscle cutting through the underlying fat until the sternohyoid muscle was exposed. The trachea was exposed and the thyroid gland located. The isthmus was then held and the thyroid gland was separated from the trachea. TX animals were given 2 to 4% calcium lactate solution as a drinking source for the duration of the experiment. HYPO animals were administered MDMA (40 mg/kg s.c.) or saline 72 h postsurgery. TX and their corresponding shams were treated with MDMA (40 mg/kg s.c.) or saline 1-week postsurgery.
Drugs and Chemicals
Cyanopindolol, a
3-receptor antagonist, was purchased from Tocris
Cookson, Inc. (Ellisville, MO). MDMA was generously donated by Dr.
David E. Nichols (Purdue University, West Lafayette, IN). Prazosin, an
1-receptor antagonist, and all other reagents were purchased from Sigma-Aldrich (St. Louis, MO) or VWR Scientific Products
(Columbus, OH).
MDMA Effects on Thermogenesis. Basal skeletal muscle and/or rectal temperatures were taken in all animals before administering MDMA or saline. Skeletal muscle temperatures were taken in the biceps femoris using a thermocouple with the electrode inserted into an 18-gauge needle. Rectal temperatures were taken with a rectal probe (Physitemp Instruments, Clifton, NJ) attached to the thermocouple and white petrolatum was applied to the probe before insertion. Skeletal muscle and rectal temperatures were taken at 1, 2, and 3 h post-treatment. Skeletal muscle temperatures were not monitored in TX animals due to the stress of the surgeries in general.
Assessment of MDMA-Induced Serotonergic Neurotoxicity.
To
assess neurotoxicity, 5-HT levels were measured from each hemisphere of
the striatum and hippocampus 7 days after treatment. TX animals were
assessed 4 days post-treatment. Samples were collected by brain
dissection of the specific brain regions over ice. Tissue samples were
then frozen in liquid nitrogen and stored at
80°C until analysis
could be performed. These samples were subsequently sonicated, using a
sonic dismembrator (Fisher Scientific Co., Pittsburgh, PA), for 15 s at a setting of approximately 4 while suspended in 100 µl of mobile phase.
MDMA Effects on Thyroxine (T4) Levels. Twelve Sprague-Dawley rats were assigned to receive saline or MDMA (40 mg/kg s.c.) to assess the effects of MDMA on T4 levels 1 h post-MDMA administration. The 1-h time point was selected based on previous results that showed MDMA-induced hyperthermia to be most robust at the 1-h time point. Animals were anesthetized using chloroform and blood was subsequently drawn from the left ventricle. Measurement of T4 levels was conducted with a Snap T4 Test. Snap T4 test is an enzyme linked immunosorbent assay for the quantitative measurement of total T4 in serum. The Snap T4 test uses a competitive enzyme immunoassay format.
In the test procedure, the serum sample is first incubated with an anti-T4 antibody-enzyme conjugate. During incubation, T4 present in the serum sample will bind to the conjugate. The T4 concentration is then calculated from the ratio of T4 test stripe color to reference stripe color developed from standard curves (R2 = 0.95) with detection limits of 0.4 µg/dl.Statistical Analysis.
Data were analyzed by analysis of
variance with a Student-Newman-Keuls post hoc test or a t
test. Significance was set at p
0.05. All
biochemical measurements were based on tissue wet weight and are
represented as percentage of saline control for ease of presentation.
Control groups in all studies were treated with saline only. All figure
legends contain the control values and sample size.
| |
Results |
|---|
|
|
|---|
Effects of MDMA on Rat Rectal and Skeletal Muscle Temperature.
MDMA induced a statistically significant increase (p < 0.01) in rat rectal (Fig. 1A) and
skeletal muscle (Fig. 1B) temperature at the 1-, 2-, and 3-h time
points.
|
Effects of Hypophysectomy on MDMA-Induced Hyperthermia.
MDMA
produced a significant (p < 0.001) increase in rectal
temperature at the 1-, 2-, and 3-h time points. Treatment of HYPO animals with the same dose of MDMA resulted in a significant
(p < 0.001) decrease in rectal temperature at the 2- and 3-h time points. Similar results were seen in the skeletal muscle
temperature measurements (Fig. 2). MDMA
yielded a significant (p < 0.001) increase in skeletal
muscle temperatures at the 1-, 2-, and 3-h time points. In contrast,
the HYPO animals treated with MDMA demonstrated a significant
(p < 0.001) decrease in skeletal muscle temperatures at the 1-, 2-, and 3-h time points.
|
Effects of Hypophysectomy on MDMA-Induced Serotonergic
Neurotoxicity.
Striatal 5-HT concentrations were significantly
(p < 0.03) decreased in the MDMA treatment group
compared with sham only (Fig. 3A).
Hippocampal 5-HT concentrations were also significantly
(p < 0.01) decreased in the MDMA treatment group
compared with all other treatment groups (Fig. 3B). Hypophysectomy
attenuated this decrease in 5-HT levels seen in both regions.
|
Effects of MDMA on T4 Levels.
MDMA induced a
significant (p < 0.007) increase in
T4 levels 1 h post-treatment. Theses results
are shown in Fig. 4.
|
Effects of Thyroparathyroidectomy on MDMA-Induced
Hyperthermia.
As was seen in the HYPO animals,
thyroparathyroidectomy resulted in a hypothermic response
(p < 0.01) after treatment with MDMA. MDMA alone
induced a significant (p < 0.01) elevation in rectal
temperature. The thyroparathyroidectomized treatment group began the
study with a baseline temperature that was significantly (p < 0.05) less than the sham control group (Fig.
5A).
|
Effects of Levothyroxine Supplementation on MDMA-Induced Thermogenic Response in TX Animals. Replacing thyroid hormones with levothyroxine (100 µg/kg s.c. × 5 days) resulted in a significant hyperthermic response compared with control (p < 0.01) albeit still significantly less than MDMA alone (p < 0.01). TX animals treated with MDMA only responded with a significant (p < 0.001) hypothermic response (Fig. 5B).
Effects of Thyroparathyroidectomy on MDMA-Induced Serotonergic
Neurotoxicity.
Striatal 5-HT concentrations were significantly
(p < 0.01) decreased in the MDMA treatment group
compared with sham only (Fig. 6A).
Hippocampal 5-HT concentrations were also significantly
(p < 0.01) decreased in the MDMA treatment group
compared with all other treatment groups (Fig. 6B).
Thyroparathyroidectomy attenuated this decrease in 5-HT levels seen in
both regions.
|
Effects of Prazosin on MDMA-Induced Hyperthermia.
The
1-receptor antagonist prazosin significantly
(p < 0.01) attenuated this rise in rectal temperature
but did not completely eliminate the hyperthermic response (Fig.
7). In the prazosin only treatment group,
rectal temperatures remained constant throughout the monitoring period
(data not shown). MDMA resulted in a significant (p < 0.001) hypothermia in the TX animals that was significantly (p < 0.05) potentiated by prazosin at the 3-h time
point.
|
|
Effects of Cyanopindolol on MDMA-Induced Hyperthermia.
The
3-receptor antagonist cyanopindolol had no
effect on the MDMA-mediated increase in rectal temperature but
significantly (p < 0.001) attenuated the increase in
skeletal muscle temperature (Fig. 9B).
Combining cyanopindolol and prazosin eliminated the hyperthermic
response in both the rectum and skeletal muscle (Fig. 10).
|
|
| |
Discussion |
|---|
|
|
|---|
Here, we show that when administered to rats, MDMA acutely
increases plasma levels of thyroid hormone T4 and
induces a similarly acute and robust elevation in core and skeletal
muscle temperatures. Surgical removal of either the pituitary or
thyroid glands abolished the hyperthermic response and produced a
significant hypothermia, in addition to blocking subsequent
serotonergic neurotoxicity, consistent with previous evidence
suggesting that the neurotoxic effects of MDMA are greatly influenced
by the hyperthermic response (Broening et al., 1995
; Farfel and Seiden,
1995
; Malberg and Seiden, 1998
). Hyperthermia was specifically
associated with elevations in thyroid hormone and TX animals showed a
hyperthermic response to MDMA when thyroid hormone was replaced. We
confirmed previous data (Pedersen and Blessing, 2001
;
Fernandez et al., 2002
) suggesting that MDMA-induced activation of the
SNS contributes to the hyperthermic response using antagonists of
1- and
3-adrenergic
receptors prazosin and cyanopindolol, respectively. To date, MDMA
research has focused exclusively on drug-induced changes in core
temperatures using rectal probes exclusively, and these techniques may
inadvertently overlook the possibility that hyperthermia may arise from
heat generation in different tissue sites. By using thermocouple
devices to record rectal and skeletal muscle temperature, we observed that
1- and
3-adrenergic antagonists differentially
attenuated hyperthermia according to the tissue examined, supporting
the notion that the hyperthermic response to MDMA is heterogeneous and
may be the result of heat generation and differential perfusion within
multiple tissues. Alone, each drug only partially blocked the
hyperthermic response in skeletal muscle (cyanopindolol) or core
(prazosin). Combination pretreatment with the antagonists, however,
completely blocked MDMA-induced hyperthermia in both locations,
strongly suggesting that combination sympatholytic drug therapy may be
a superior acute treatment option for clinical cases of MDMA-mediated hyperthermia.
Based on the findings of Pedersen and Blessing (2001)
suggesting that
cutaneous vasoconstriction contributes to the increase in core
temperature seen after treatment with MDMA, and those of McDaid and
Docherty (2001)
showing that the vascular effects of MDMA seem to
involve predominately
1-adrenergic receptors, we tested the effects of prazosin on MDMA-mediated thermogenesis. Our
results showing only a partial attenuation of the core hyperthermia by
prazosin parallel those of Pedersen and Blessing (2001)
, who saw only a
partial antagonism with surgical sympathectomy. The ganglionic blocker
chlorisondamine has also been shown to reduce the amplitude of the
hyperthermia induced by MDMA (Fernandez et al., 2002
). Based upon these
studies, we hypothesized that MDMA-induced core hyperthermia would be
attenuated with prazosin pretreatment. Our results with prazosin's
effects on MDMA-mediated core temperature changes confirmed these
previous observations. Skeletal muscle hyperthermia was, however,
unaffected by
1-blockade.
Skeletal muscle thermogenesis occurs by three primary mechanisms: 1)
contraction, or shivering, 2) thermogenic calcium cycling mediated by
the dantrolene-sensitive ryanodine receptor (Paul-Pletzer et al.,
2002
), and 3) activation of mitochondrial proton leak by UCP-3, which
is highly expressed in skeletal muscle and has recently been associated
with skeletal muscle thermogenesis in transgenic mice overexpressing
UCP-3 (Curtin et al., 2002
) and yeast (Hinz et al., 1999
). Dantrolene
is the primary pharmacological line of defense in hospitalizations for
MDMA-induced hyperthermia (Dar and McBrien, 1996
). Despite its
widespread use, dantrolene fails to adequately control the hyperthermic
response seen after MDMA ingestion (Dar and McBrien, 1996
). In animals,
the skeletal muscle relaxant xylazine also fails to reduce the
hyperthermic response (our unpublished observations). These data
suggest that other mechanisms may contribute more readily to hyperthermia.
UCP-3 is both induced and activated by increased intracellular cAMP
downstream of
3-adrenergic receptors and
thyroid hormone (Gong et al., 1997
).
3-Adrenergic agonists and thyroid hormone are
thought to produce a synergistic activation of thermogenesis in animals
(Silva, 1995
). In the present study, the
3-antagonist, cyanopindolol, attenuated the
rise in skeletal muscle temperature after MDMA treatment but had no
effect on core temperature. Together, the data suggests that
mitochondrial UCP-3 may contribute to increased skeletal muscle
temperatures after MDMA.
Three other lines of evidence suggest that UCPs may be involved in the
thermogenic response to MDMA. First, clinical presentations of severe
hyperthermia induced by MDMA can include rhabdomyolysis, wherein
skeletal muscle cells lose viability, lyse, and release myoglobin,
which can lead to renal failure (Walubo and Seger, 1999
). We recently
demonstrated that overexpression of UCP-2, a homolog of UCP-3, induces
ATP depletion and oncosis in transiently transfected and retrovirally
infected cultured cells (Mills et al., 2002
). Second, we recently
reported that MDMA regulates the levels of UCP-3 mRNA in rat skeletal
muscle (Sprague et al., 2002
). Third, MDMA has also been shown to
increase proton leak in rat striatum, a specific functional correlate
of UCP activity (Burrows et al., 2000
).
MDMA-mediated dopamine release and subsequent activation of
hypothalamic D1 receptors has been shown to play
an essential role in this hyperthermic response (Mechan et al., 2002
).
Activation of the hypothalamic axis following MDMA treatment is also
confirmed by increased c-fos expression in the supraoptic and median
preoptic nucleus of the hypothalamus following MDMA treatment
(Stephenson et al., 1999
). Curiously, our hypophysectomized and
thyroparathyroidectomized animals showed a hypothermic response to
MDMA. Hypothyroidism has been shown to stimulate the SNS by increasing
the amounts of norepinephrine in the plasma (Coulombe and Dussault,
1977
). Despite increased amounts of norepinephrine, the normal
thermogenic response to norepinephrine and cold is blunted in
hypothyroid animals (Triandafillou et al., 1982
; Sundin et al., 1984
),
supporting the notion that thyroid hormone plays a permissive role in
SNS-mediated thermogenesis. According to Bianco et al. (1988)
, this
blunted response is probably due to a reduced synergistic action
between T3 and norepinephrine at the gene level.
In the absence of T3, as would presumably be the
case with our thyroparathyroectomized animals, the norepinephrine
response would be attenuated (Bianco et al., 1988
). This defect in the
norepinephrine signaling pathway may alter the stimulatory action of
cAMP on UCP-3 activity and/or expression (Gripois and Valens, 1982
;
Young et al., 1982
). Hypothyroidism has also been associated with an
up-regulation of
1- (Dicker et al., 1992
) and
3-receptors (Rubio et al., 1995b
) and a
down-regulation of
1- and
2-receptors (Rubio et al., 1995a
). We cannot
rule out the possibility that changes in sympathetic receptor levels in
our TX animals may well play a role in the hypothermic response seen in
this study. Our data showing that levothyroxine supplementation restores the hyperthermic response to MDMA further supports our hypothesis that thyroid hormone is required for MDMA-mediated thermogenesis.
Much controversy surrounds the role of hyperthermia in the neurotoxic
effects of MDMA in experimental animals. The
5-HT2A/2C receptor antagonists ketanserin (Nash,
1990
) and MDL 11,939 (Schmidt, 1987
) not only prevent the
neurotoxicity but also block the hyperthermia induced by a low dose (10 mg/kg) of MDMA. In both of these reports, higher doses of MDMA still
produced hyperthermia, but serotonergic neurotoxicity was nevertheless
blocked. Malberg et al. (1996)
showed that the ability of ketanserin to
block the neurotoxicity of MDMA is lost by increasing the body
temperature of the animal. Those authors further reported that
pretreatment of the animals with
-methyl-para-tyrosine, a
tyrosine hydroxylase inhibitor, induced hypothermia and prevented the
neurotoxicity of subsequently administered MDMA, but that warming the
animals negated these protective effects. Although these data clearly
suggest a link between hyperthermia and subsequent neurotoxicity, not
all agents that prevent MDMA-induced neurotoxicity necessarily do so by
blocking the hyperthermic response. Fluoxetine fails to prevent
MDMA-induced hyperthermia, yet still affords protection against the
neurotoxic process (Malberg et al., 1996
). Antisense oligonucleotides
targeting monoamine oxidase-B (Falk et al., 2002
) or the dopamine
transporter (Kanthasamy et al., 2002
) also attenuate the serotonergic
neurotoxicity induced by MDMA without altering the hyperthermic response.
Lowering body temperature protects against brain damage induced by a
variety of insults, most likely by simply slowing neurochemical processes. Bowyer et al. (1993)
showed that if animals were placed in a
cold environment, both dopamine release and neurotoxicity induced by
methamphetamine treatment were decreased. Thus, agents that reduce body
temperature may decrease the neurochemical effects of MDMA and provide
protection against its acute peripheral effects and chronic
neurotoxicity. Our results using surgically modified animals are
consistent with previous suggestions that blocking hyperthermia
protects against subsequent neurotoxicity. As our data also suggest,
however, hypothermia may be required for the magnitude of neurologic
protection observed in our studies.
The results of the present study and supporting evidence that is extant
in the literature would argue strongly for an interactive role between
the SNS and the HPT axis in the hyperthermic response to MDMA. We
propose that MDMA acutely activates the HPT axis and the SNS, and
stimulates thyroid-,
1-adrenergic-, and
3-adrenergic-dependent core and skeletal
muscle hyperthermia by the activation of uncoupling proteins.
Furthermore, we propose that clinical intervention consistent with this
mechanism of MDMA-induced hyperthermia may prove superior in protecting
individuals from some of the acute peripheral and delayed neurological
toxicities that may be seen after MDMA misuse.
| |
Acknowledgments |
|---|
We are grateful for technical assistance provided by Dr. David Houx and Michele Smith in the assessment of T4 levels. We are also appreciative of the generous gift of MDMA by Dr. David E. Nichols and of the constructive comments provided by Dr. Toren Finkel during the preparation of this manuscript.
| |
Footnotes |
|---|
Accepted for publication December 18, 2002.
Received for publication September 30, 2002.
This research was sponsored by an Undergraduate Research Initiative Grant and funded by the Ohio Northern University College of Pharmacy.
DOI: 10.1124/jpet.102.044982
Address correspondence to: Dr. Jon E. Sprague, Associate Professor of Pharmacology, Department of Pharmaceutical and Biomedical Sciences, The Raabe College of Pharmacy, Ohio Northern University, Ada, OH 45810. E-mail: j-sprague{at}onu.edu
| |
Abbreviations |
|---|
MDMA, 3,4-methylenedioxymethamphetamine; SNS, sympathetic nervous system; UCP, uncoupling proteins; HPT, hypothalamic-pituitary-thyroid; HYPO, hypophysectomized; TX, thyroparathyroidectomized; 5-HT, 5-hydroxytryptamine, serotonin; T4, thyroxine.
| |
References |
|---|
|
|
|---|
1-adrenoceptor density in brown adipose tissue indicates recruitment drive in hypothyroid rats.
Am J Physiol
263:
E654-E662
3-adrenergic agonists and leptin.
J Biol Chem
272:
24129-24132
1 and
2-adrenoceptors in the anaesthetized rat.
Br J Pharmacol
133:
429-439[CrossRef][Medline].
1- and
2-Adrenergic receptors and cyclic adenosine monophosphate generation.
Endocrinology
136:
3267-3276[Abstract].
3-adrenergic receptors in brown and white adipose tissue.
Endocrinology
136:
3277-3284[Abstract].This article has been cited by other articles:
![]() |
M. L. Banks, J. E. Sprague, D. F. Kisor, P. W. Czoty, D. E. Nichols, and M. A. Nader Ambient Temperature Effects on 3,4-Methylenedioxymethamphetamine-Induced Thermodysregulation and Pharmacokinetics in Male Monkeys Drug Metab. Dispos., October 1, 2007; 35(10): 1840 - 1845. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Nagamine and Y. Sakakibara Statistical prediction of protein chemical interactions based on chemical structure and mass spectrometry data Bioinformatics, August 1, 2007; 23(15): 2004 - 2012. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Sprague, X. Yang, J. Sommers, T. L. Gilman, and E. M. Mills Roles of Norepinephrine, Free Fatty Acids, Thyroid Status, and Skeletal Muscle Uncoupling Protein 3 Expression in Sympathomimetic-Induced Thermogenesis J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 274 - 280. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Rusyniak, S. L. Tandy, S. K. Hekmatyar, E. Mills, D. J. Smith, N. Bansal, D. MacLellan, M.-E. Harper, and J. E. Sprague The Role of Mitochondrial Uncoupling in 3,4-Methylenedioxymethamphetamine-Mediated Skeletal Muscle Hyperthermia and Rhabdomyolysis J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 629 - 639. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||